-
1
-
-
58049157203
-
Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis
-
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Secondgeneration versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41.
-
(2009)
Lancet
, vol.373
, Issue.9657
, pp. 31-41
-
-
Leucht, S.1
Corves, C.2
Arbter, D.3
Engel, R.R.4
Li, C.5
Davis, J.M.6
-
2
-
-
60349086480
-
A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia
-
Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152-163.
-
(2009)
Am J Psychiatry
, vol.166
, Issue.2
, pp. 152-163
-
-
Leucht, S.1
Komossa, K.2
Rummel-Kluge, C.3
-
3
-
-
77952410794
-
Clinical usefulness of olanzapine in bipolar disorder - a developer's insight
-
Tohen M, Treuer T. Clinical usefulness of olanzapine in bipolar disorder - a developer's insight. US Psyc. 2009;2(1):32-36.
-
(2009)
US Psyc
, vol.2
, Issue.1
, pp. 32-36
-
-
Tohen, M.1
Treuer, T.2
-
4
-
-
79952718641
-
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC)
-
Strom BL, Eng SM, Faich G, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011;168(2):193-201.
-
(2011)
Am J Psychiatry
, vol.168
, Issue.2
, pp. 193-201
-
-
Strom, B.L.1
Eng, S.M.2
Faich, G.3
-
5
-
-
34547218869
-
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison
-
McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060.
-
(2007)
Am J Psychiatry
, vol.164
, Issue.7
, pp. 1050-1060
-
-
McEvoy, J.P.1
Lieberman, J.A.2
Perkins, D.O.3
-
6
-
-
40949142200
-
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial
-
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618): 1085-1097.
-
(2008)
Lancet
, vol.371
, Issue.9618
, pp. 1085-1097
-
-
Kahn, R.S.1
Fleischhacker, W.W.2
Boter, H.3
-
7
-
-
25144456112
-
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
-
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223.
-
(2005)
N Engl J Med
, vol.353
, Issue.12
, pp. 1209-1223
-
-
Lieberman, J.A.1
Stroup, T.S.2
McEvoy, J.P.3
-
8
-
-
33846558834
-
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
-
Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17(4):235-244.
-
(2007)
Eur Neuropsychopharmacol
, vol.17
, Issue.4
, pp. 235-244
-
-
Haro, J.M.1
Suarez, D.2
Novick, D.3
Brown, J.4
Usall, J.5
Naber, D.6
-
9
-
-
35648936485
-
Reviewing CATIE for clinicians: Balancing benefit and risk using evidence-based medicine tools
-
Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin. 2007;23(10):2551-2557.
-
(2007)
Curr Med Res Opin
, vol.23
, Issue.10
, pp. 2551-2557
-
-
Karagianis, J.1
Rosenbluth, M.2
Tohen, M.3
-
10
-
-
0025086423
-
From noncompliance to collaboration in the treatment of schizophrenia
-
Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry. 1990;41(11):1203-1211.
-
(1990)
Hosp Community Psychiatry
, vol.41
, Issue.11
, pp. 1203-1211
-
-
Corrigan, P.W.1
Liberman, R.P.2
Engel, J.D.3
-
11
-
-
0036773689
-
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature
-
Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63(10):892-909.
-
(2002)
J Clin Psychiatry
, vol.63
, Issue.10
, pp. 892-909
-
-
Lacro, J.P.1
Dunn, L.B.2
Dolder, C.R.3
Leckband, S.G.4
Jeste, D.V.5
-
12
-
-
34347347003
-
Adherence to atypical antipsychotic treatment among newly treated patients: A population-based study in schizophrenia
-
Cooper D, Moisan J, Grégoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry. 2007;68(6):818-825.
-
(2007)
J Clin Psychiatry
, vol.68
, Issue.6
, pp. 818-825
-
-
Cooper, D.1
Moisan, J.2
Grégoire, J.P.3
-
13
-
-
33947170567
-
Olanzapine orally-disintegrating tablet in severe psychotic agitation: A naturalistic study
-
Pascual JC, Pérez V, Martín JL, Safont G, Puigdemont D, Alvarez E. Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study. Actas Esp Psiquiatr. 2007;35(1):47-51.
-
(2007)
Actas Esp Psiquiatr
, vol.35
, Issue.1
, pp. 47-51
-
-
Pascual, J.C.1
Pérez, V.2
Martín, J.L.3
Safont, G.4
Puigdemont, D.5
Alvarez, E.6
-
14
-
-
0004050325
-
-
American Psychiatric Association, 2nd ed. Arlington, VA: American Psychiatric Association
-
American Psychiatric Association. Practice Guideline for the Treatment of Patients with Schizophrenia. 2nd ed. Arlington, VA: American Psychiatric Association; 2004.
-
(2004)
Practice Guideline for the Treatment of Patients with Schizophrenia
-
-
-
15
-
-
33645458077
-
Clinical practice guidelines. Treatment of schizophrenia
-
Canadian Psychiatric Association
-
Canadian Psychiatric Association. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005;50(13 Suppl 1):7S-57S.
-
(2005)
Can J Psychiatry
, vol.50
, Issue.13 SUPPL. 1
-
-
-
16
-
-
79960298257
-
Adherence to antipsychotic drug treatment in earlyepisode schizophrenia: A six-month naturalistic follow-up study
-
Baloush-Kleinman V, Levine SZ, Roe D, Shnitt D, Weizman A, Poyurovsky M. Adherence to antipsychotic drug treatment in earlyepisode schizophrenia: a six-month naturalistic follow-up study. Schizophr Res. 2011;130(1-3):176-181.
-
(2011)
Schizophr Res
, vol.130
, Issue.1-3
, pp. 176-181
-
-
Baloush-Kleinman, V.1
Levine, S.Z.2
Roe, D.3
Shnitt, D.4
Weizman, A.5
Poyurovsky, M.6
-
17
-
-
0036736320
-
Olanzapine oro-dispersible (Velotab) - an alternative to depot?
-
Johnson D, Rai S, Milne S. Olanzapine oro-dispersible (Velotab) - an alternative to depot? Int J Psychiatry Clin Pract. 2002;6(3):163-165.
-
(2002)
Int J Psychiatry Clin Pract
, vol.6
, Issue.3
, pp. 163-165
-
-
Johnson, D.1
Rai, S.2
Milne, S.3
-
18
-
-
49849089222
-
Olanzapine orally disintegrating tablet: A review of efficacy and compliance
-
San L, Casillas M, Ciudad A, Gilaberte I. Olanzapine orally disintegrating tablet: a review of efficacy and compliance. CNS Neurosci Ther. 2008;14(3):203-214.
-
(2008)
CNS Neurosci Ther
, vol.14
, Issue.3
, pp. 203-214
-
-
San, L.1
Casillas, M.2
Ciudad, A.3
Gilaberte, I.4
-
19
-
-
26844467822
-
Fast dissolving tablets: New dosage convenience for patients
-
Bogner RH, Wilkosz MF. Fast dissolving tablets: new dosage convenience for patients. US Pharm. 2002;27:34-43.
-
(2002)
US Pharm
, vol.27
, pp. 34-43
-
-
Bogner, R.H.1
Wilkosz, M.F.2
-
21
-
-
0031958859
-
Drug-delivery products and the Zydis fast-dissolving dosage form
-
Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50(4):375-382.
-
(1998)
J Pharm Pharmacol
, vol.50
, Issue.4
, pp. 375-382
-
-
Seager, H.1
-
22
-
-
0036810029
-
Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia
-
Chue P, Jones B, Taylor CC, Dickson R. Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia. Can J Psychiatry. 2002;47(8):771-774.
-
(2002)
Can J Psychiatry
, vol.47
, Issue.8
, pp. 771-774
-
-
Chue, P.1
Jones, B.2
Taylor, C.C.3
Dickson, R.4
-
23
-
-
77957119044
-
Rapid onset of absorption with olanzapine orally disintegrating tablets
-
Bergstrom RF, Mitchell M, Witcher J, et al. Rapid onset of absorption with olanzapine orally disintegrating tablets. J Emerg Nurs. 2004;30(5):416-417.
-
(2004)
J Emerg Nurs
, vol.30
, Issue.5
, pp. 416-417
-
-
Bergstrom, R.F.1
Mitchell, M.2
Witcher, J.3
-
24
-
-
31344474686
-
Pharmacokinetics and bioequivalence of olanzapine rapidly-disintegrating tablets
-
Witcher JW, Bergstrom RF, Cerimele BJ, et al. Pharmacokinetics and bioequivalence of olanzapine rapidly-disintegrating tablets. Pharm Sci. 1998;1(1):S487.
-
(1998)
Pharm Sci
, vol.1
, Issue.1
-
-
Witcher, J.W.1
Bergstrom, R.F.2
Cerimele, B.J.3
-
25
-
-
31344479789
-
Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers
-
Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol. 2006;46(2):164-171.
-
(2006)
J Clin Pharmacol
, vol.46
, Issue.2
, pp. 164-171
-
-
Markowitz, J.S.1
de Vane, C.L.2
Malcolm, R.J.3
-
26
-
-
84857094393
-
-
Poster presented at: 10th World Congress of Biological Psychiatry; May 29-June 2, Prague, Czech Republic
-
Hobbs D, Karagianis J, Treuer T, Raskin J. An in vitro analysis of disintegration times of different formulations of orally disintegrating olanzapine. Poster presented at: 10th World Congress of Biological Psychiatry; May 29-June 2, 2011. Prague, Czech Republic.
-
(2011)
An in Vitro Analysis of Disintegration Times of Different Formulations of Orally Disintegrating Olanzapine
-
-
Hobbs, D.1
Karagianis, J.2
Treuer, T.3
Raskin, J.4
-
27
-
-
67650090764
-
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS study
-
Karagianis J, Grossman L, Landry J, et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS study. Schizophr Res. 2009;113(1):41-48.
-
(2009)
Schizophr Res
, vol.113
, Issue.1
, pp. 41-48
-
-
Karagianis, J.1
Grossman, L.2
Landry, J.3
-
28
-
-
77957129707
-
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
-
Bitter I, Treuer T, Dilbaz N, et al. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry. 2010; 11(7):894-903.
-
(2010)
World J Biol Psychiatry
, vol.11
, Issue.7
, pp. 894-903
-
-
Bitter, I.1
Treuer, T.2
Dilbaz, N.3
-
29
-
-
84857068977
-
-
Paper presented at: 8th Biennial Australasian Schizophrenia Conference; September 22-24, Brisbane, Australia
-
Damodaran S, D'Souza R, Katz P, et al. An Australian observational study of olanzapine tablet and wafer formulations for the treatment of inpatients with schizophrenia. Paper presented at: 8th Biennial Australasian Schizophrenia Conference; September 22-24, 2004. Brisbane, Australia.
-
(2004)
An Australian Observational Study of Olanzapine Tablet and Wafer Formulations for the Treatment of Inpatients with Schizophrenia
-
-
Damodaran, S.1
D'Souza, R.2
Katz, P.3
-
30
-
-
49449106319
-
Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients
-
Czekalla J, Wagner T, Schacht A, Kluge M, Kinon B. Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients. Patient Prefer Adherence. 2007;1:19-27.
-
(2007)
Patient Prefer Adherence
, vol.1
, pp. 19-27
-
-
Czekalla, J.1
Wagner, T.2
Schacht, A.3
Kluge, M.4
Kinon, B.5
-
31
-
-
84857070209
-
Actual state of use of orally disintegrating olanzapine tablets in patients with acute-stage schizophrenia
-
Kuramochi M, Nishiuma S, Tanji U, Fujikoshi S, Fuchigami Y, Takahashi M. Actual state of use of orally disintegrating olanzapine tablets in patients with acute-stage schizophrenia. Rinsho Seishin Yakuri. 2009;12:2159-2168.
-
(2009)
Rinsho Seishin Yakuri
, vol.12
, pp. 2159-2168
-
-
Kuramochi, M.1
Nishiuma, S.2
Tanji, U.3
Fujikoshi, S.4
Fuchigami, Y.5
Takahashi, M.6
-
32
-
-
84857086344
-
Effectiveness of olanzapine coated and orally disintegrating tablets in a 1-year European observational study
-
Chartier F, Rouillon F, Lukasiewicz M, Kraemer S, D'yachkova Y. Effectiveness of olanzapine coated and orally disintegrating tablets in a 1-year European observational study. Eur Neuropsychopharmacol. 2010;20(Suppl 3):S508-S509.
-
(2010)
Eur Neuropsychopharmacol
, vol.20
, Issue.SUPPL. 3
-
-
Chartier, F.1
Rouillon, F.2
Lukasiewicz, M.3
Kraemer, S.4
D'Yachkova, Y.5
-
33
-
-
45549085098
-
Olanzapine orally disintegrating tablet vs risperidone oral solution in the treatment of acutely agitated psychotic patients
-
Hatta K, Kawabata T, Yoshida K, et al. Olanzapine orally disintegrating tablet vs risperidone oral solution in the treatment of acutely agitated psychotic patients. Gen Hosp Psychiatry. 2008;30(4):367-371.
-
(2008)
Gen Hosp Psychiatry
, vol.30
, Issue.4
, pp. 367-371
-
-
Hatta, K.1
Kawabata, T.2
Yoshida, K.3
-
34
-
-
77952404770
-
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan
-
Hsu WY, Huang SS, Lee BS, Chiu NY. Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan. J Clin Psychopharmacol. 2010;30(3):230-234.
-
(2010)
J Clin Psychopharmacol
, vol.30
, Issue.3
, pp. 230-234
-
-
Hsu, W.Y.1
Huang, S.S.2
Lee, B.S.3
Chiu, N.Y.4
-
35
-
-
33846596713
-
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients
-
Arranz B, San L, Dueñas RM, et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol. 2007;22(1): 11-15.
-
(2007)
Hum Psychopharmacol
, vol.22
, Issue.1
, pp. 11-15
-
-
Arranz, B.1
San, L.2
Dueñas, R.M.3
-
36
-
-
77949507803
-
Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: An open-label prospective study
-
Hori H, Ueda N, Yoshimura R, et al. Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World J Biol Psychiatry. 2009;10(4 Pt 3):741-745.
-
(2009)
World J Biol Psychiatry
, vol.10
, Issue.4 PART 3
, pp. 741-745
-
-
Hori, H.1
Ueda, N.2
Yoshimura, R.3
-
37
-
-
49849094151
-
Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: An observational prospective study
-
Dardennes R, Chartier F, Heurtebize N, Olivier V, Perrin E. Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: an observational prospective study. Int J Neuropsychopharmacol. 2004;7(Suppl 2):P01-P389.
-
(2004)
Int J Neuropsychopharmacol
, vol.7
, Issue.SUPPL. 2
-
-
Dardennes, R.1
Chartier, F.2
Heurtebize, N.3
Olivier, V.4
Perrin, E.5
-
38
-
-
0037827154
-
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia
-
Kinon BJ, Hill AL, Liu H, Kollack-Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol. 2003;6:97-102.
-
(2003)
Int J Neuropsychopharmacol
, vol.6
, pp. 97-102
-
-
Kinon, B.J.1
Hill, A.L.2
Liu, H.3
Kollack-Walker, S.4
-
39
-
-
84857096124
-
The effect of using orally disintegrating olanzapine tablets on agitation, cooperation and nurses' workload in psychiatric patients
-
Van Heeringen C, Vandendriessche F, Van Vleymen B, Gillain B. The effect of using orally disintegrating olanzapine tablets on agitation, cooperation and nurses' workload in psychiatric patients. Acta Psychiatr Belg. 2006;106:14-19.
-
(2006)
Acta Psychiatr Belg
, vol.106
, pp. 14-19
-
-
van Heeringen, C.1
Vandendriessche, F.2
van Vleymen, B.3
Gillain, B.4
-
40
-
-
0023606101
-
The positive and negative syndrome scale (PANSS) for schizophrenia
-
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
-
(1987)
Schizophr Bull
, vol.13
, Issue.2
, pp. 261-276
-
-
Kay, S.R.1
Fiszbein, A.2
Opler, L.A.3
-
41
-
-
0003412410
-
-
National Institute of Mental Health, Rockville, MD: US Department of Health, Education, and Welfare
-
Guy W. National Institute of Mental Health. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
-
(1976)
ECDEU Assessment Manual for Psychopharmacology
-
-
Guy, W.1
-
42
-
-
14944363483
-
Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention and management
-
Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28(3):191-208.
-
(2005)
Drug Saf
, vol.28
, Issue.3
, pp. 191-208
-
-
Pierre, J.M.1
-
43
-
-
0036942527
-
Predictors of noncompliance in patients with schizophrenia
-
Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry. 2002;63(12):1121-1128.
-
(2002)
J Clin Psychiatry
, vol.63
, Issue.12
, pp. 1121-1128
-
-
Perkins, D.O.1
-
44
-
-
79957794555
-
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder
-
Citrome L, Holt RI, Walker DJ, Hoffmann VP. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin Drug Investig. 2011;31(7):455-482.
-
(2011)
Clin Drug Investig
, vol.31
, Issue.7
, pp. 455-482
-
-
Citrome, L.1
Holt, R.I.2
Walker, D.J.3
Hoffmann, V.P.4
-
45
-
-
47249148105
-
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
-
Karagianis J, Hoffmann VP, Arranz B, et al. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol. 2008;23(4):275-281.
-
(2008)
Hum Psychopharmacol
, vol.23
, Issue.4
, pp. 275-281
-
-
Karagianis, J.1
Hoffmann, V.P.2
Arranz, B.3
-
46
-
-
5444233534
-
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets
-
de Haan L, van Amelsvoort T, Rosien K, Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl). 2004;175(3): 389-390.
-
(2004)
Psychopharmacology (Berl)
, vol.175
, Issue.3
, pp. 389-390
-
-
de Haan, L.1
van Amelsvoort, T.2
Rosien, K.3
Linszen, D.4
-
47
-
-
33744958755
-
Long-term treatment with atypical antipsychotics and risk of weight gain
-
Stip E, Anselmo K, Wolfe M, Lessard C, Landry P. Long-term treatment with atypical antipsychotics and risk of weight gain. Drug Saf. 2006;29(6):550-552.
-
(2006)
Drug Saf
, vol.29
, Issue.6
, pp. 550-552
-
-
Stip, E.1
Anselmo, K.2
Wolfe, M.3
Lessard, C.4
Landry, P.5
-
48
-
-
35348992825
-
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets
-
Crocq MA, Guillon MS, Bailey PE, Provost D. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry. 2007;22(7):453-454.
-
(2007)
Eur Psychiatry
, vol.22
, Issue.7
, pp. 453-454
-
-
Crocq, M.A.1
Guillon, M.S.2
Bailey, P.E.3
Provost, D.4
-
49
-
-
42549153837
-
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial
-
Chawla B, Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum Psychopharmacol. 2008;23(3):211-216.
-
(2008)
Hum Psychopharmacol
, vol.23
, Issue.3
, pp. 211-216
-
-
Chawla, B.1
Luxton-Andrew, H.2
-
50
-
-
77957874979
-
Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: A randomized crossover study
-
Vidarsdottir S, Vlug P, Roelfsema F, Frölich M, Pijl H. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry. 2010;71(9):1205-1211.
-
(2010)
J Clin Psychiatry
, vol.71
, Issue.9
, pp. 1205-1211
-
-
Vidarsdottir, S.1
Vlug, P.2
Roelfsema, F.3
Frölich, M.4
Pijl, H.5
-
51
-
-
73949102385
-
Short-term treatment with olanzapine does not modulate gut hormone secretion: Olanzapine disintegrating versus standard tablets
-
Vidarsdottir S, Roelfsema F, Streefland T, Holst JJ, Rehfeld JF, Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur J Endocrinol. 2010;162(1):75-83.
-
(2010)
Eur J Endocrinol
, vol.162
, Issue.1
, pp. 75-83
-
-
Vidarsdottir, S.1
Roelfsema, F.2
Streefland, T.3
Holst, J.J.4
Rehfeld, J.F.5
Pijl, H.6
-
52
-
-
84855614689
-
Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: A randomized, open comparison in outpatients with bipolar depression
-
Bobo WV, Epstein RA Jr, Shelton RC. Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression. Ann Clin Psychiatry. 2011;23(3):193-201.
-
(2011)
Ann Clin Psychiatry
, vol.23
, Issue.3
, pp. 193-201
-
-
Bobo, W.V.1
Epstein Jr., R.A.2
Shelton, R.C.3
-
53
-
-
71649109370
-
Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: Data from a clinical study that was terminated early
-
Hoffmann VP, Case M, Jacobson JG, Francis JL. Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: data from a clinical study that was terminated early. Schizophr Res. 2009;115(2-3):370-371.
-
(2009)
Schizophr Res
, vol.115
, Issue.2-3
, pp. 370-371
-
-
Hoffmann, V.P.1
Case, M.2
Jacobson, J.G.3
Francis, J.L.4
-
54
-
-
77956835783
-
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs orally disintegrating olanzapine: The PLATYPUS study
-
Karagianis J, Landry J, Hoffmann VP, et al. An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs orally disintegrating olanzapine: the PLATYPUS study. Int J Clin Pract. 2010;64(11):1520-1529.
-
(2010)
Int J Clin Pract
, vol.64
, Issue.11
, pp. 1520-1529
-
-
Karagianis, J.1
Landry, J.2
Hoffmann, V.P.3
-
55
-
-
0028307292
-
Incorporating patients' preferences into medical decisions
-
Kassirer JP. Incorporating patients' preferences into medical decisions. New Engl J Med. 1994;330(26):1895-1896.
-
(1994)
New Engl J Med
, vol.330
, Issue.26
, pp. 1895-1896
-
-
Kassirer, J.P.1
-
56
-
-
18844416899
-
Preferences for medical collaboration: Patient-physician congruence and patient outcomes
-
Jahng KH, Martin LR, Golin CE, DiMatteo MR. Preferences for medical collaboration: patient-physician congruence and patient outcomes. Patient Educ Couns. 2005;57(3):308-314.
-
(2005)
Patient Educ Couns
, vol.57
, Issue.3
, pp. 308-314
-
-
Jahng, K.H.1
Martin, L.R.2
Golin, C.E.3
di Matteo, M.R.4
-
57
-
-
0028785232
-
Identifying modifiable risk factors for rehospitalization: A case-control study of seriously mentally ill persons in Mississippi
-
Sullivan G, Wells KB, Morgenstern H, Leake B. Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry. 1995;152(12): 1749-1756.
-
(1995)
Am J Psychiatry
, vol.152
, Issue.12
, pp. 1749-1756
-
-
Sullivan, G.1
Wells, K.B.2
Morgenstern, H.3
Leake, B.4
-
58
-
-
0036673659
-
Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission
-
Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002;40(8):630-639.
-
(2002)
Med Care
, vol.40
, Issue.8
, pp. 630-639
-
-
Valenstein, M.1
Copeland, L.A.2
Blow, F.C.3
-
59
-
-
39549111228
-
A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia
-
Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69(1):47-53.
-
(2008)
J Clin Psychiatry
, vol.69
, Issue.1
, pp. 47-53
-
-
Law, M.R.1
Soumerai, S.B.2
Ross-Degnan, D.3
Adams, A.S.4
-
60
-
-
65649098979
-
Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
-
Ascher-Svanum H, Zhu B, Faries DE, Furiak NM, Montgomery W. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Res Notes. 2009;2:6.
-
(2009)
BMC Res Notes
, vol.2
, pp. 6
-
-
Ascher-Svanum, H.1
Zhu, B.2
Faries, D.E.3
Furiak, N.M.4
Montgomery, W.5
-
61
-
-
76849096676
-
The cost of relapse and the predictors of relapse in the treatment of schizophrenia
-
Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry. 2010;10:2.
-
(2010)
BMC Psychiatry
, vol.10
, pp. 2
-
-
Ascher-Svanum, H.1
Zhu, B.2
Faries, D.E.3
-
62
-
-
77949772157
-
Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia
-
Novick D, Haro JM, Suarez D, Perez V, Dittmann RW, Haddad PM. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res. 2010;176(2-3):109-113.
-
(2010)
Psychiatry Res
, vol.176
, Issue.2-3
, pp. 109-113
-
-
Novick, D.1
Haro, J.M.2
Suarez, D.3
Perez, V.4
Dittmann, R.W.5
Haddad, P.M.6
-
63
-
-
0029051754
-
Cost of relapse in schizophrenia
-
Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21(3):419-429.
-
(1995)
Schizophr Bull
, vol.21
, Issue.3
, pp. 419-429
-
-
Weiden, P.J.1
Olfson, M.2
-
64
-
-
0029072904
-
Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders
-
Haywood TW, Kravitz HM, Grossman LS, Cavanaugh JL Jr, Davis JM, Lewis DA. Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry. 1995;152(6):856-861.
-
(1995)
Am J Psychiatry
, vol.152
, Issue.6
, pp. 856-861
-
-
Haywood, T.W.1
Kravitz, H.M.2
Grossman, L.S.3
Cavanaugh Jr., J.L.4
Davis, J.M.5
Lewis, D.A.6
-
65
-
-
0036536942
-
Medication compliance and comorbid substance abuse in schizophrenia: Impact on community survival 4 years after a relapse
-
Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substance abuse in schizophrenia: impact on community survival 4 years after a relapse. Schizophr Res. 2002;54(3):253-264.
-
(2002)
Schizophr Res
, vol.54
, Issue.3
, pp. 253-264
-
-
Hunt, G.E.1
Bergen, J.2
Bashir, M.3
-
66
-
-
2342521323
-
Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment
-
Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004;30(1):3-20.
-
(2004)
Schizophr Bull
, vol.30
, Issue.1
, pp. 3-20
-
-
Swanson, J.W.1
Swartz, M.S.2
Elbogen, E.B.3
-
67
-
-
33646132967
-
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
-
Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.
-
(2006)
BMC Psychiatry
, vol.6
, pp. 8
-
-
Ascher-Svanum, H.1
Zhu, B.2
Faries, D.3
Landbloom, R.4
Swartz, M.5
Swanson, J.6
-
68
-
-
65649093241
-
Adherence and persistence to typical and atypical antipsychotics in the treatment of schizophrenia
-
Ascher-Svanum H, Zhu B, Faries DE, Lacro JP, Dolder CR, Peng X. Adherence and persistence to typical and atypical antipsychotics in the treatment of schizophrenia. Patient Prefer Adherence. 2008;2:67-77.
-
(2008)
Patient Prefer Adherence
, vol.2
, pp. 67-77
-
-
Ascher-Svanum, H.1
Zhu, B.2
Faries, D.E.3
Lacro, J.P.4
Dolder, C.R.5
Peng, X.6
-
69
-
-
34248579125
-
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: An integrated analysis
-
Beasley CM Jr, Stauffer VL, Liu-Seifert H, Taylor CC, Dunayevich E, Davis JM. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J Clin Psychopharmacol. 2007;27(3):252-258.
-
(2007)
J Clin Psychopharmacol
, vol.27
, Issue.3
, pp. 252-258
-
-
Beasley Jr., C.M.1
Stauffer, V.L.2
Liu-Seifert, H.3
Taylor, C.C.4
Dunayevich, E.5
Davis, J.M.6
-
70
-
-
77952071928
-
The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: Consistency across world geographies and study designs
-
Novick D, Ascher-Svanum H, Zhu B, et al. The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs. Pharmacopsychiatry. 2010;43(3):81-85.
-
(2010)
Pharmacopsychiatry
, vol.43
, Issue.3
, pp. 81-85
-
-
Novick, D.1
Ascher-Svanum, H.2
Zhu, B.3
-
71
-
-
57849125864
-
Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study
-
Haro JM, Novick D, Suarez D, Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009;43(3):265-273.
-
(2009)
J Psychiatr Res
, vol.43
, Issue.3
, pp. 265-273
-
-
Haro, J.M.1
Novick, D.2
Suarez, D.3
Roca, M.4
-
72
-
-
0030065502
-
Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
-
Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14(2):111-123.
-
(1996)
Neuropsychopharmacology
, vol.14
, Issue.2
, pp. 111-123
-
-
Beasley Jr., C.M.1
Tollefson, G.2
Tran, P.3
Satterlee, W.4
Sanger, T.5
Hamilton, S.6
-
73
-
-
26444456116
-
Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia
-
Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162(10):1879-1887.
-
(2005)
Am J Psychiatry
, vol.162
, Issue.10
, pp. 1879-1887
-
-
Breier, A.1
Berg, P.H.2
Thakore, J.H.3
-
74
-
-
60349104833
-
Long-term antipsychotic monotherapy for schizophrenia: Disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study
-
Dossenbach M, Pecenak J, Szulc A, et al. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study. J Clin Psychiatry. 2008;69(12):1901-1915.
-
(2008)
J Clin Psychiatry
, vol.69
, Issue.12
, pp. 1901-1915
-
-
Dossenbach, M.1
Pecenak, J.2
Szulc, A.3
-
75
-
-
65449123582
-
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia
-
Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009;70(4):572-581.
-
(2009)
J Clin Psychiatry
, vol.70
, Issue.4
, pp. 572-581
-
-
Kane, J.M.1
Osuntokun, O.2
Kryzhanovskaya, L.A.3
-
76
-
-
30044439100
-
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: A pooled posthoc analysis of four atypical antipsychotic drugs
-
Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled posthoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:21.
-
(2005)
BMC Med
, vol.3
, pp. 21
-
-
Liu-Seifert, H.1
Adams, D.H.2
Kinon, B.J.3
-
77
-
-
34548586774
-
Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder
-
Dunayevich E, Ascher-Svanum H, Zhao F, et al. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychiatry. 2007;68(8): 1163-1171.
-
(2007)
J Clin Psychiatry
, vol.68
, Issue.8
, pp. 1163-1171
-
-
Dunayevich, E.1
Ascher-Svanum, H.2
Zhao, F.3
-
78
-
-
3543124260
-
Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia
-
Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55(8):886-891.
-
(2004)
Psychiatr Serv
, vol.55
, Issue.8
, pp. 886-891
-
-
Weiden, P.J.1
Kozma, C.2
Grogg, A.3
Locklear, J.4
-
79
-
-
0034971802
-
Using drug claims data to assess the relationship of medication adherence with hospitalization and costs
-
Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv. 2001;52(6):805-811.
-
(2001)
Psychiatr Serv
, vol.52
, Issue.6
, pp. 805-811
-
-
Svarstad, B.L.1
Shireman, T.I.2
Sweeney, J.K.3
-
80
-
-
0037527741
-
An economic review of compliance with medication therapy in the treatment of schizophrenia
-
Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv. 2003;54(4):508-516.
-
(2003)
Psychiatr Serv
, vol.54
, Issue.4
, pp. 508-516
-
-
Thieda, P.1
Beard, S.2
Richter, A.3
Kane, J.4
|